• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Yesterday’s Migraine Call

















Qulipta is at 16% growth since the launch meeting. The target is 40% growth. It’s also lost ground to the MABs since the meeting. Ubrelvy is mostly flat. Solution from the brand and management team is to message harder with the challenger sale…….
 




Qulipta is at 16% growth since the launch meeting. The target is 40% growth. It’s also lost ground to the MABs since the meeting. Ubrelvy is mostly flat. Solution from the brand and management team is to message harder with the challenger sale…….

Bahaha

Here is some good branding:

Qulipta is the ONLY ONCE DAILY ORAL treatment for episodic migraine

Ubrelvy gets patients to pain freedom faster than any other medication and can be taken up to 2 hours into a migraine

C'mon after years of saying this Ubrelvy and Qulipta couldn't cut it? Damn
 




Bahaha

Here is some good branding:

Qulipta is the ONLY ONCE DAILY ORAL treatment for episodic migraine

Ubrelvy gets patients to pain freedom faster than any other medication and can be taken up to 2 hours into a migraine

C'mon after years of saying this Ubrelvy and Qulipta couldn't cut it? Damn


It's good to see our competition is unfamiliar with the majority of our message.
 




It's good to see our competition is unfamiliar with the majority of our message.

The competition is probably unfamiliar because you sell inferior medicine and use shit loads of money to buy doctors lunch so they maybe write ONCE so you can run off to your manager and show them that you are a good little rep who gets doctors to write!
 




The competition is probably unfamiliar because you sell inferior medicine and use shit loads of money to buy doctors lunch so they maybe write ONCE so you can run off to your manager and show them that you are a good little rep who gets doctors to write!

Ummm, what? What are you... 12? That was a pretty weak comeback. Do better next time.
 




The bottom line is no coverage. The drug will be 4 years old and the coverage in our state is piss poor. Come on AbbVie! You can do better than this. Totally unacceptable